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Background: In India, there is an urgent need to enhance the
hematopoietic stem cell transplant (HSCT) facilities. It is also
important to be certain that these procedures can be carried
out within the existing infrastructure of hospitals with
requisite expertise. Although, there is a sudden rise in
numbers of transplant centres in last 2-3 years, there is still a
lack of dedicated HSCT units equipped with special air-
handling facilities and high efﬁciency air (HEPA) ﬁlter rooms.
It is important to ascertain the safety of performing allogenic
HSCT in single rooms without HEPA ﬁlters.
Aim: To evaluate short and long term outcomes of allogenic
HSCT performed in non-HEPA ﬁltered single rooms.
Patients and Methods: We analysed ﬁrst 123 consecutive
patients, who underwent an allogenic HSCT performed in
non-HEPA ﬁltered air-conditioned single rooms with barrier
nursing over 7 years from July 2005 to August 2012. The
preferred source of stem cells was GCSF mobilised peripheral
blood stem cells (PBSC). In small donors, where PBSC was
technically difﬁcult, bone marrow was harvested under
general anaesthesia. All patients received antibacterial,
antifungal and antiviral prophylaxis. At the onset of fever,
systemic antibiotics were started. Antifungal agents were
added if fever persisted for 3 days.
Results: We present our experience of performing 123
consecutive HLA matched sibling donor allogenic trans-
plantations. Source of stem cells was peripheral blood in 105
(85.4%), bonemarrow in 16 (13.0%) and combined in 1 (0.8%),
and one died during the period conditioning regimen was
administered before infusion of stem cells. The indications
were severe aplastic anemia (SAA) 58 (47.2%), CML 16 (13%),
AML 17 (13.8%), ALL 7 (5.7%), biphenotypic AL 3 (2.4%),
thalassemia/CDA 17 (13.8%) andmyelodysplastic syndrome 4
(3.2%), PRCA 1 (0.8%). The mean age was 23.8 years (range:2.2 e 52 years, SD: 12.5 years) with 28 (22.8%) females and
95 (77.2%) males. Mean CD34 cell dose was 5.35 x 106/kg
(range: 0.7 e 10.24, SD: 2.08). Median time to neutrophil
engraftment was 10 days (range 8 e 21 days). Two patients
with thalassemia major who received bone marrow as stem
cell source did not engraft and succumbed to fungal pneu-
monia. Fever occurred in 104 (85.6%) patients for a median of
6 days (range 2 e 10 days). Systemic antibiotics were used in
all thosewho had fever and antifungals in 48 (39%) cases. The
30 day mortality was 11 (8.9%) and 100 day mortality was 17
(13.8%). There were 26 (21.1%) fatalities in total, due to failure
to engraft 2, platelet refractoriness leading to intracranial
bleed 2, VOD 2, relapse 3, graft rejection 3, acute GvHD 3,
chronic GvHD 2, infections like disseminated TB 3 and
aspergillosis 6.
Conclusion: The result of this study highlights the fact that
allogenic BMT can be performed successfully with manage-
able toxicity in majority of cases under resource crunch
settings.369
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Background: Clostridium difﬁcile infection (CDI) is one of
the leading causes of hospital-acquired infections in recent
times. Hematopoietic stem cell transplantation (HSCT) con-
fers increased risk for CDI because of prolonged hospital stay,
immunosuppression, the need to use broad spectrum anti-
biotics and a complex interplay of preparative regimen and
graft versus host disease (GVHD)-induced gut mucosal
damage. Although there have been studies describing the
epidemiology and risk factors (RF) for CDI in HSCT recipients,
there are little data regarding recurrence rate of CDI and RF
associated with recurrence in this particular patient popu-
lation, especially given the ubiquity of traditional RF for CDI
in this population.
Aim: To evaluate the recurrence rate and RF associated with
recurrent CDI in allogeneic HSCT recipients.
Design and Methods: We conducted a retrospective, single
center study of 499 allogeneic HSCT recipients transplanted
between 2005 and 2012; of these, 61 (12%) developed CDI
within 6 months prior to transplant or 2 years after trans-
plant and were included in the analysis. Recurrent CDI was
deﬁned as recurrence after appropriate treatment of ﬁrst
episode which occurred in 20 (33%) of patients. Variables
including age, antibiotic use, proton pump inhibitor use,
presence of GVHD and other patient and transplant charac-
teristics were analyzed as potential RFs for recurrence.
Results: The 61 patients had a median age of 49 yrs (range 2-
73 yrs) and M:F ratio of 1.1. 74% received myeloablative
regimen and 26% received non-myeloablative regimen for
HSCTand acute GVHDwas seen in 59% of patients. Once-year
incidence of CDI recurrence in our study was 31% compared
tow20% recurrence in other series. Fine and Gray regression
analysis identiﬁed the number of antecedent antibiotics
other than those used to treat CDI as the only signiﬁcant RF
for recurrence (Hazard ratio (HR) 1.96, 95% Conﬁdence In-
terval (CI) 1.09-3.52, P ¼ 0.025). Most recurrences occurred
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CDI was associated with a trend for increased risk of mor-
tality (HR 2.36 [95% CI 0.98-5.71], P ¼ 0.06).
Conclusion: Use of antecedent antibiotics other than those
used to treat CDI was associated with an increased risk of
recurrent CDI in allogeneic HSCT recipients. CDI recurrence
rate is high in the ﬁrst 6months following ﬁrst episode of CDI
and is associated with a trend for increased risk of mortality.
This prompts the need for further investigation into sec-
ondary prophylaxis to prevent recurrent CDI.370
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Allogeneic stem cell transplant (SCT) remains the only
curative option for patients with b thalassemia major (TM).
Graft rejections post SCT are unfortunately a common
problem in this condition. There is limited data on the clin-
ical proﬁle and long term outcome of patients who have had
a graft rejection post allogeneic SCT.
From October, 1991 to April, 2013, 400 HLA matched related
transplants for TM was done at our center. The median age
was 8 years (range: 1-24) and there were 250 (62.5%) males.
154 (38.5%) were Lucarelli Class II and 229 (57.2%) were in the
Class III risk group. Majority (72%) received a busulfan based
conditioning regimen while 22% received a treosulfan based
regimen. Bone marrow was the source of stem cells in 81%
and PBSC in the rest.
There were 48 (12%) graft rejections in this cohort. Among
these 26 (54%) were primary graft failures (PGF) while 22
(46%) were secondary graft failures (SGF). The median time
to a SGF was 122 days (range: 40 - 2210). Of the 26 PGF,
9(34.6%) had autologous recovery with recurrence of trans-
fusion dependence while 17(65.4%) had pancytopenia.
11(42.3%) of PGF died prior to second transplant, 10 (38.5%)
had a second transplant and the rest had recurrence of TM
but were alive and well. Among the 22 SGF, 10(45.5%) had
autologous recovery. Of the SGF’s, 2 died prior to a second
transplant while 9 had a second transplant and the
remaining (n¼11) had recurrence of TM and were on con-
servative management.
Among the 29 cases that did not receive a second transplant
14 died at a median time of 20 days (range: 0-3268). The
major cause of death in this group was graft failure with
infection (n¼10) and regimen related toxicity (RRT; n¼4).
The remaining cases (n¼14) are alive and well on conser-
vative management (transfusion dependent, one with
pancytopenia).
19 (39.%) of the patients with graft rejection underwent a
second allogeneic SCT. Conditioning regimen for second SCT
was busulfan based in 5(26.3%), treosulfan based in 5(26.3%)
and the rest received non-myeloablative conditioning regi-
mens (ﬂudarabine based, low dose TBI, OKT3, Cy-OKT3) in
view of pancytopenia. The source of stem cells was BM in
7(36.84%) and PBSC in the rest. All cases conditioned with
treosulfan based regimen received a PBSC graft. The OS and
EFS of the patients that had a second transplant was
41.412.8% and 37.612.2% respectively. None of the patients
conditioned with a treosulfan based regimen died or had asecond graft rejection. Of the remaining 14 patients 11 died
of second graft rejection while 3 (all busulfan based condi-
tioning) are alive and well at 3, 23 and 81 months from
second transplant.
In conclusion graft rejection following allogeneic SCT for
patients with TM are associated with poor clinical outcomes.
A treosulfan based reduced toxicity myeloablative regimen
with a PBSC graft has potential to signiﬁcantly improve the
outcome in this group of patients.371
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Objective: To investigate the tolerance to 400 cGy of total
body irradiation (TBI) as part of a myeloablative conditioning
regimen for hematopoietic stem cell transplantation (HSCT)
and to identify factors inﬂuencing tolerance to TBI.
Patients and method: We conducted a prospective study
grading the tolerance to 400 cGy of TBI combined with Flu-
darabine and Busulfan as myeloablative-conditioning (Flu-
BuTBI) for HSCT. FluBuTBI consists of Fludarabine 50 mg/m2/
day x 5 days), Busulfan (3.2 mg/kg/day x 4 days) and total
body irradiation (200 cGy/day x 2 days). We also conducted
an exploratory analysis for factors affecting tolerance. Thirty-
six (36) patients received FluBuTBI. We graded tolerance to
TBI as Very Good (VG) e minor breaks during treatment
overall treatment time not doubled, Good (G) e important
breaks, treatment time at least doubled and Poor (P) emajor
breaks with clinical toxicity of E (emesis), D (diarrhea), or S
(syncopal episode). We grouped VG and G as one category
with 19 patients (VG¼12 + G¼7), and poor as the other
category (n¼16). We then analyzed age, sex, BMI, remission
status, comorbidity index, Karnofsky score comparing the 2
categories. Diagnoses included AML (n¼13), ALL (n¼4), NHL
(n¼13), Hodgkin lymphoma (n¼3) and CML (n¼1). Twenty
(20) patients underwent allogeneic and 16 autologous
transplant.
Results: Median age was 45 years in the VG/G category
versus 54 years in the P category (p¼0.11). 74% of patients in
the VG/G category were male versus 35% of patients in the P
category (p¼ 0.02). Heavily pre-treated was 37% in VG/G
category and 88% in the P category (p¼ 0.0009). The BMI was
identical in both the groups at 30. The HCT-CI was also
similar in both groups with medians of 1.6 (VG/G group) and
1.9 (P group). The Karnofsky scorewas 90 in both groups. 47%
of patients in the VG/G group and 41% of patients in the P
group were in complete remission. 74% patients in the VG/G
category underwent allogeneic transplant while only 29% of
patients in the P category did so (p¼0.002).
Conclusion: Our data shows that sex and prior therapy affect
tolerance to TBI. Males tolerated TBI better than females.
Patients who were heavily pretreated tolerated TBI less well.
Surprisingly, Karnofsky score, HCT-CI, disease and BMI had
no effect on the tolerance to TBI. Better prophylactic strategy
is warranted in the at risk population. Factors affecting
tolerance to TBI deserves further study in a larger cohort.
